ImmunityBio, Inc. (IBRX) vs 10x Genomics, Inc. (TXG)
A side-by-side comparison of ImmunityBio, Inc. and 10x Genomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IBRX
ImmunityBio, Inc.
$9.69HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TXG
10x Genomics, Inc.
$80.66HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IBRX vs TXG
growth of $100 · dividends reinvested · last 7yIBRX +646.8% (+33.3%/yr)TXG +85.3% (+9.2%/yr)IBRX compounded faster over this window
IBRX TXG
IBRX vs TXG: by the numbers
- •TXG is the larger company ($10.24B vs $10.15B market cap).
- •Both run net losses; TXG's is the smaller (-12.18% vs -598.56% net margin).
- •IBRX grew revenue faster over the past five years (202.97% vs 8.74% CAGR).
Metrics side by side
Valuation
| Metric | IBRX | TXG |
|---|---|---|
| P/S ratio | 61.21 | 16.60 |
| P/B ratio | N/A | 12.40 |
| FCF yield | N/A | 1.19% |
Profitability
| Metric | IBRX | TXG |
|---|---|---|
| Gross margin | 94.63% | 70.03% |
| Operating margin | -226.00% | -14.33% |
| Net margin | -598.56% | -12.18% |
| ROE | N/A | -9.10% |
| ROIC | -45.63% | -9.57% |
Growth (annualized)
| Metric | IBRX | TXG |
|---|---|---|
| Revenue CAGR (5Y) | 202.97% | 8.74% |
| Total return CAGR (5Y) | 0.39% | -7.24% |
Frequently asked
- Which has grown faster, IBRX or TXG?
- Over the past five years, IBRX grew revenue faster — IBRX at a 202.97% CAGR versus TXG at 8.74%.
- How have IBRX and TXG total returns compared?
- Over the past 5 years, IBRX delivered 0.39% and TXG delivered -7.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ImmunityBio ROE10x Genomics ROEImmunityBio operating margin10x Genomics operating marginImmunityBio revenue growth10x Genomics revenue growthImmunityBio free cash flow10x Genomics free cash flow
ImmunityBio & 10x Genomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.